Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lupin

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

Boehringer creates ‘Captain Zantac’

Animated fireman fronts marketing campaign in US for heartburn remedy

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

- PMLiVE

Boehringer: clinical trial set-up poses challenge in rare diseases

Says more support needed in regulatory process for orphan drugs

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links